Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233659 | 0.78 | APP (0.32) | — | |
| SCHEMBL30361758 | 0.73 | SMN1; SMN2 (0.39) | SMN1; SMN2GMNNALDH1A1LMNATP53 | |
| SCHEMBL28491524 | 0.71 | TP53 (0.48) | SMN1; SMN2GMNNALDH1A1LMNATP53 | |
| SCHEMBL28760816 | 0.71 | — | — | |
| SCHEMBL1486205 | 0.70 | — | — | |
| SCHEMBL25674276 | 0.69 | SMN1; SMN2 (0.39) | SMN1; SMN2GMNNALDH1A1LMNATP53 | |
| SCHEMBL19564446 | 0.67 | SMN1; SMN2 (0.47) | SMN1; SMN2GMNNALDH1A1LMNATP53 | |
| SCHEMBL18319467 | 0.67 | EPHX2 (0.38) | SMN1; SMN2GMNNALDH1A1LMNATP53 | |
| SCHEMBL3424157 | 0.66 | ALDH1A1 (0.55) | SMN1; SMN2GMNNALDH1A1LMNATP53 | |
| SCHEMBL29947797 | 0.66 | TP53 (0.48) | SMN1; SMN2GMNNALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230001024-A1 | CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| EP-4054561-A1 | CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF | North Carolina State University (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20220275111-A1 | CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2022-09-01 | — | — | US | disclosed |
| US-20220267479-A1 | POLYIODIDE BINDING COMPOUNDS AND METHODS OF USE THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| EP-4003363-A1 | CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF | North Carolina State University (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267479-A1 | POLYIODIDE BINDING COMPOUNDS AND METHODS OF USE THEREOF | SHBG, PCNA, INHA | SMN1; SMN2 4707/4885GMNN 1249/4885ALDH1A1 3461/4885 |
| US-20230001024-A1 | CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF | AOX1, MTCL3, COL1A1 | SMN1; SMN2 2650/4885GMNN 2264/4885ALDH1A1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.